Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy

Hay, Ian; Lee, Robert A.; Davidge‐Pitts, Caroline; Reading, Carl C.; Charboneau, J. William

doi:10.1016/j.surg.2013.07.007

Cited by 113 publications

(93 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding less invasive alternatives, recent publications demonstrated that percutaneous ethanol injection produced favorable results for control of recurrent thyroid cancers (10)(11)(12)(13)(14)(15).…”

Section: Methodsmentioning

confidence: 99%

Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm

Kim¹,

Yoo²,

Park³

et al. 2015

Radiology

123

106

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm

Kim¹,

Yoo²,

Park³

et al. 2015

Radiology

123

106

View full text Add to dashboard Cite

show abstract

“…Both the RIA and LC-MS/MS class of method can achieve only first-generation functional sensitivity. Increasingly, laboratories are replacing first-generation tests with Tg 2G IMA measurement because superior functional sensitivity allows basal (non-TSH stimulated) Tg 2G IMA monitoring to replace the need for rhTSH stimulation [16 ▪▪ ,17–20,45–52] and facilitate the detection of the low thyroglobulin concentrations arising from postoperative thyroid remnants [53 ▪▪ ] and lymph node metastases secreting low levels of thyroglobulin [54,55]. Unfortunately, as with all IMA-class methods, Tg 2G IMAs are highly prone to interference from both HAMA and TgAb, potentially limiting their clinical value [3 ▪▪ ,30 ▪▪ ].…”

Section: Review Of Four Decades Of Thyroglobulin Methodologymentioning

confidence: 99%

How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies

Spencer

LoPresti

Fatemi

2014

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewTo discuss new insights regarding how sensitive (second-generation) thyroglobulin immunometric assays (Tg2GIMAs), (functional sensitivities ≤0.10 μg/L) necessitate different approaches for postoperative thyroglobulin monitoring of patients with differentiated thyroid cancer (DTC), depending on the presence of thyroglobulin autoantibodies (TgAbs).Recent findingsReliable low-range serum thyroglobulin measurement has both enhanced clinical utility and economic advantages, provided TgAb is absent (∼75% DTC patients). Basal [nonthyroid-stimulating hormone (TSH) stimulated] Tg2GIMA measurement obviates the need for recombinant human TSH stimulation because basal Tg2GIMA below 0.20 μg/L has comparable negative predictive value (>95%) to recombinant human TSH-stimulated thyroglobulin values below the cutoff of 2 μg/L. Now that radioiodine remnant ablation is no longer considered necessary to treat low-risk DTC, the trend and doubling time of low basal thyroglobulin values arising from postsurgical thyroid remnants have recognized prognostic significance. The major limitation of Tg2GIMA testing is interference by TgAb (∼25% DTC patients), causing Tg2GIMA underestimation that can mask disease. When TgAb is present, the trend in TgAb concentrations (measured by the same method) can serve as the primary (surrogate) tumor-marker and be augmented by thyroglobulin measured by a TgAb-resistant class of method (radioimmunoassay or liquid chromatography-tandem mass spectrometry).SummaryThe growing use of Tg2GIMA measurement is changing paradigms for postoperative DTC monitoring. When TgAb is absent, it is optimal to monitor the basal Tg2GIMA trend and doubling time (using the same method) in preference to recombinant human TSH-stimulated thyroglobulin testing. When TgAb is present, interference renders Tg2GIMA testing unreliable and the trend in serum TgAb concentrations per se (same method) can serve as a (surrogate) tumor-marker.

show abstract

“…Among the three kinds of thyroid cancers, PTC is the main form of thyroid cancer, whose morbidity is the highest and accounting for approximately 80 %, while ATC is the most aggressive solid and its 5-year survival rate is 3 to 5 months after diagnosis [3,4]. Previous studies refer that radiation, chemotherapy, and surgery are the common treatment methods for thyroid cancer, but they all produce poor satisfactory [5,6]. In addition to genetic and environmental factors, increasing papers have shown that epigenetic alteration may play pivotal roles in the development and progression of various kinds of tumors including thyroid cancer [7,8].…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR)

et al. 2015

View full text Add to dashboard Cite

The purposes of this study were to investigate the potential roles of long noncoding RNA (lncRNA) PVT1 in thyroid cancer cell proliferation and to explore their possible mechanisms. A total of 84 patients who were diagnosed as having thyroid cancer (papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and anaplastic thyroid carcinoma (ATC)) in Renji Hospital were enrolled in this study. Expressions of lncRNA PVT1 in thyroid cancer tissues and cell lines (IHH-4, FTC-133, and 8505C) were analyzed using RT-polymerase chain reaction (PCR) and western blotting analysis. The effects of lncRNA PVT1 expression on thyroid cancer cell proliferation and cell cycle were analyzed using flow cytometry. Furthermore, the effects of lncRNA expression on thyroid-stimulating hormone receptor (TSHR) expression and polycomb enhancer of zeste homolog 2 (EZH2) were also analyzed using RNA immunoprecipitation (RIP) assay and chromatin immunoprecipitation (ChIP) assay, respectively. Compared to the controls, lncRNA PVT1 was significantly up-regulated in thyroid tissues, as well as in three kinds of tumor cell lines (P < 0.05). Silenced PVT1 significantly inhibited thyroid cell line IHH-4, FTC-133, and 8505C cell proliferation and arrested cell cycle at G0/G1 stage and significantly decreased cyclin D1 and TSHR expressions (P < 0.05). Moreover, lncRNA PVT1 could be enriched by EZH2, and silencing PVT1 resulted in the decreased recruitment of EZH2. This study suggested that lncRNA PVT1 may contribute to tumorigenesis of thyroid cancer through recruiting EZH2 and regulating TSHR expression.

show abstract

Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy

Cited by 113 publications

References 21 publications

Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm

Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm

How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies

Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR)

Contact Info

Product

Resources

About